Quantcast
Last updated on April 21, 2014 at 10:19 EDT

Latest hypertriglyceridemia Stories

2013-12-05 08:29:55

CAMBRIDGE, Mass., Dec. 5, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals, Inc., today announced the initiation of a Phase 2 clinical trial investigating the safety and efficacy of CAT-2003 in patients with severe hypertriglyceridemia, defined as serum triglyceride levels of 500 mg/dL or greater. CAT-2003 is a conjugate of niacin and the omega 3 fatty acid, eicosapentaenoic acid (EPA), employing Catabasis' proprietary SMART Linker technology. In this second Phase 2 trial of CAT-2003,...

2013-08-28 08:26:32

-- Catabasis CMO to Present at PACE Conference in Amsterdam -- CAMBRIDGE, Mass., Aug. 28, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals, Inc., today announced that new clinical data on the inhibition of PSCK9* by its oral SMART Linker conjugate, CAT-2003, will be presented at the Physicians Academy for Continuing Education (PACE) conference in Amsterdam on Aug. 31 by Catabasis' chief medical officer, Joanne Donovan, M.D., Ph.D., during the "Novel interventions in cardiovascular disease:...

2013-08-21 08:25:56

CAMBRIDGE, Mass., Aug. 21, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals Inc. today announced the initiation of PATHWAYS I*, a Phase 2 trial investigating the safety, tolerability and efficacy of CAT-2003, an oral SMART Linker conjugate constructed using the company's proprietary technology. CAT-2003 will be evaluated in patients with hypertriglyceridemia and in combination with statins in patients with hypercholesterolemia. "We recently announced positive Phase 1 data showing...

2013-07-30 08:33:54

-- Achieves Improvements in Biomarkers PCSK9, ApoB and LDL -- CAMBRIDGE, Mass., July 30, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals, Inc., today announced that preliminary data from a Phase 1 trial of CAT-2003, an oral SMART Linker conjugate constructed using the company's proprietary technology, demonstrated a significant reduction in fasting and post-prandial triglyceride levels. CAT-2003 also had positive effects on other biomarkers, including reductions in apolipoprotein...

2013-06-23 12:20:06

Improvements in glucose control and insulin sensitivity also observed CARLSBAD, Calif., June 23, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that data from the Phase 2 study of ISIS-APOCIII(Rx) in patients with high triglycerides and type 2 diabetes were presented today at the American Diabetes Association Scientific Sessions in Chicago. In this study, patients treated with ISIS-APOCIII(Rx) experienced an 88 percent reduction in apolipoprotein C-III...

2013-06-06 08:29:40

PARSIPPANY, N.J., June 6, 2013 /PRNewswire/ -- Recent guidance from the American Association of Clinical Endocrinologists (AACE) highlight for the first time a cardiovascular risk factor management algorithm that identifies treatments of dyslipidemia in patients with type 2 diabetes.(1 )In these new guidelines, Welchol(®) (colesevelam HCI) is the only therapy recognized that provides patients with a dual-benefit: it helps to lower both A1C and LDL cholesterol ("bad" cholesterol or LDL-C)...

2013-05-28 04:21:04

PRINCETON, N.J., May 28, 2013 /PRNewswire/ -- AstraZeneca today announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, New Jersey, focused on the development and commercialization of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia. Omthera's investigational product, Epanova(TM), for the potential treatment of patients with very high triglycerides, is a novel...

2013-03-26 08:29:28

CAMBRIDGE, Mass., March 26, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals Inc., today announced the initiation of a Phase 1 study to investigate the safety and tolerability of CAT-2003 in healthy volunteers and in adults with mildly elevated lipids. CAT-2003 is a conjugate of niacin and eicosapentaenoic acid (EPA), an omega-3 fatty acid, covalently linked using the company's proprietary SMART Linker technology to create a new chemical entity and is being developed for patients...

2013-02-04 12:25:34

TEWKSBURY, N.J. and TARPON SPRINGS, Fla., Feb. 4, 2013 /PRNewswire/ -- Matinas BioPharma, Inc., a biopharmaceutical company focused on the commercialization and development of omega-3-based prescription therapeutics for the treatment of metabolic and cardiovascular conditions, announced today that Roelof Rongen, Matinas BioPharma's Chief Executive Officer, is scheduled to present at the NYC Medical Technology Forum on Tuesday, February 5, 2013 at 6 PM EST. Mr. Rongen's presentation will...

2013-01-21 23:02:43

This study is a Phase 1, Placebo-Controlled, Randomized Trial to Assess the Safety and Tolerability of a New Drug in Obese Hyperlipidemic Adults with or without Type 2 Diabetes DeLand, Florida (PRWEB) January 21, 2013 **Avail Clinical Research is now enrolling for a Type 2 Diabetes Clinical Trial in Florida. To get started, visit Avail Clinical Research or call us directly at (386) 310-1334. BACKGROUND & RATIONALE Type 2 diabetes (T2DM) is one of the largest medical burdens in the...